NCI/NIH Award $2 Million to Immunicom to Initiate Clinical Trial Evaluating Breakthrough Immunopheresis® LW-02 Molecular Subtractive Therapy in Refractory ER+/Her2- Breast Cancer
Retrieved on:
Tuesday, June 14, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, PD-L1, BOR, CA, Baylor University, National Cancer Institute, TNBC, Biotechnology, Safety, ORR, Toxicity, Plasma, Inflammation, Breast cancer, Cancer, NIH, VEGF, Dialysis, Financial toxicity, Baylor College of Medicine, Multimedia, National Institutes of Health, FDA, Therapy, Patient, Risk, Technology, National, CE marking, Clinical trial, NCI, IL-6, PFS, RECIST, Nuclear Medicine, Oncology and Radiotherapy Institute, Pharmaceutical industry, Medical imaging, Vaccine, Column
View the full release here: https://www.businesswire.com/news/home/20220614005928/en/
Key Points:
- View the full release here: https://www.businesswire.com/news/home/20220614005928/en/
Immunicom's LW-02 molecular ligand-capture column (Photo: Business Wire)
We are honored to receive this grant from the NCI/NIH recognizing the potential of Immunopheresis therapy. - This clinical trial is a monumental step for Immunicom to address unmet needs for patients with difficult-to-treat cancers, said Principal Investigator Dr. Robert Segal, Immunicoms Chief Medical Officer.
- In a process like dialysis, Immunopheresis therapy removes sTNF-R1/2 from plasma, helping kickstart endogenous TNF- response to cancer without toxicities that increase the risk of side effects.
- Immunicom is headquartered in San Diego, CA, with operations in Houston, TX, Philadelphia, PA, Krakow, Poland, and Istanbul, Turkey.